A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

NCT00170937 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

507

Enrollment

INDUSTRY

Sponsor class

Conditions

METABOLIC SYNDROME
HYPERTENSION
PRE-HYPERTENSION

Interventions

DRUG: valsartan plus hydrochlorothiazide

Sponsor

Novartis